Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.28M$1.28Mderived−59.3% vs Q4 2024 Net Income-$14.22M-$14.22MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$13,512,000N/M Operating Cash Flowderived-$18,328,000N/M Free Cash Flowderived-$18,328,000N/M Margins · derivedOperating margin-1058.1%−830.6 pt vs Q4 2024
Net margin-1113.5%
ended Dec 31, 2025 · filed Mar 16, 2026 · 75 d after period end